SCHEMBL22833395

SCHEMBL22833395

CCOC(=O)c1ccc(C(F)(F)F)cc1Nc1ccc(F)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
LMNA P02545 2/20 0.46
TAS2R14 Q9NYV8 1/20 0.44
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
THRB P10828 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.42
TSHR P16473 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SCN8A Q9UQD0 1/20 0.42
SCN10A Q9Y5Y9 1/20 0.42
MAPT P10636 2/20 0.41
MAP2K2 P36507 1/20 0.41
MAP2K1 Q02750 1/20 0.41
MAPK1 P28482 1/20 0.41
MCL1 Q07820 1/20 0.41
CFTR P13569 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29382578 1.00 KDM4E (0.46) KDM4ELMNATAS2R14POLBSMN1; SMN2
SCHEMBL30294513 0.92 MRGPRX4 (0.45) KDM4ELMNATAS2R14POLBSMN1; SMN2
SCHEMBL22853414 0.92 MRGPRX4 (0.45) KDM4ELMNATAS2R14POLBSMN1; SMN2
SCHEMBL22852778 0.91 MAP2K2 (0.48) KDM4ELMNATAS2R14POLBSMN1; SMN2
SCHEMBL30294768 0.91 MAP2K2 (0.48) KDM4ELMNATAS2R14POLBSMN1; SMN2
SCHEMBL30294404 0.89 MRGPRX4 (0.48) KDM4ELMNAPOLBSMN1; SMN2TDP1
SCHEMBL22852785 0.89 MRGPRX4 (0.48) KDM4ELMNAPOLBSMN1; SMN2TDP1
SCHEMBL26931183 0.89 KDM4E (0.44) KDM4ELMNATAS2R14POLBSMN1; SMN2
SCHEMBL22853410 0.88 CDC25B (0.47) KDM4ELMNAPOLBSMN1; SMN2TDP1
SCHEMBL22853000 0.88 KDM4E (0.43) KDM4ELMNATAS2R14POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed
EP-3990436-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GlaxoSmithKline Intellectual Property Development Ltd (GB) 2022-05-04 EP disclosed
WO-2020261114-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-30 WO disclosed
WO-2020261114-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B KDM4E 3392/4885LMNA 686/4885TAS2R14 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.